Letter from Dr A Rejman Department of Health to Dr H Pickles Hillingdon Health Authority re Haemophilia Discusses whether use of recombinant product poses other risks not found in plasma derived products such as Factor VIII mentions testing of plasma pools for HCV HIV and hepatitis B by the manufacturers and by NIBSC Haemophilias Centre Directors proposals to give haemophiliacs plasma derived Factor VIII first before changing to recombinant Factor VIII